Paul G. Harch, M.D.
Paul G. Harch, M.D. is a Clinical Professor of Medicine, Section of Emergency Medicine at LSU School of Medicine, New Orleans, a graduate of The Johns Hopkins University School of Medicine, and a magna cum laude/Phi Beta Kappa graduate of the University of California, Irvine. Dr. Harch is the director of the University Medical Center Hyperbaric Medicine Department and separately maintains an active private practice where he has adapted the concepts of conventional hyperbaric oxygen therapy to wounds in the central nervous system. Beginning with brain injured divers and boxers he applied his protocol to the first HBOT-treated cerebral palsy and autistic children in this country and multiple other cerebral disorders. He has successfully treated U.S. servicemen with TBI and PTSD, publishing preliminary findings in the Journal of Neurotrauma, 1/2012. The studies in brain-injured veterans have continued with a randomized trial funded by a Louisiana generated congressional appropriation. His human studies were confirmed in an animal model of chronic traumatic brain injury that was published in Brain Research in October, 2007. He has presented his research seven times to the U.S. Congress and been nominated for the NIH Director’s Pioneer Award. In April, 2007 he published the Oxygen Revolution with co-author Virginia McCullough. This groundbreaking book, which has been released in its third updated edition in 5/2016, explains HBOT as a gene therapy and its projected revolutionary effects on medicine and neurology.
Dr. Harch will lecture on Oxygen Epigenetics, A Workshop on the Entire Dosing Range of Hyperbaric Oxygen Therapy October 5
In this workshop Dr. Harch will explain and define hyperbaric oxygen therapy for the first time in 350 years for what it really is, epigenetic therapy with oxygen and pressure. Elaborating on this concept which was first proposed in the third edition of his book, The Oxygen Revolution, Dr. Harch will unify the field of hyperbaric therapy from compressed air to the highest doses of pure oxygen using the scientific literature and illustrative cases documented with functional imaging. He will explain the basic biology of HBOT and review not only the applications to typically reimbursed U.S. diagnoses, but also the common off-label diagnoses including traumatic brain injury, stroke, CP, autism, cognitive decline, and degenerative diseases. Dr. Harch will review what went wrong and what went right with the recent Department of Defense TBI HBOT studies and the Collet CP trial of 2001. He will demonstrate how these studies have confused the scientific community and lay public, and, surprisingly, how they have inadvertently dramatically expanded the field of hyperbaric medicine. Lastly, Dr. Harch will discuss hyperbaric therapy dosing.
For more information on Dr. Harch please visit his Curriculum Vitae
“Neurodegeneration: The Impact of Environmental Insult”
Grand Rapids, MI, Oct 4-8, 2017
Don’t wait to get to know us! We send out pre-conference articles and information through our newsletter and social networks. Like, friend, and follow!
“Between Conference Connection,” is our weekly e-letter. Subscribe, and send us submissions of research articles for this publication.
On twitter @ICIMconference